MENU
+Compare
SUPN
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$33.05
Change
-$1.54 (-4.45%)
Capitalization
1.84B

SUPN Supernus Pharmaceuticals Forecast, Technical & Fundamental Analysis

a developer for the treatment of central nervous system

SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for SUPN with price predictions
Feb 18, 2025

SUPN's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Oscillator for SUPN moved out of overbought territory on January 28, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 instances where the indicator moved out of the overbought zone. In of the 39 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SUPN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SUPN broke above its upper Bollinger Band on February 04, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on February 13, 2025. You may want to consider a long position or call options on SUPN as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SUPN just turned positive on February 18, 2025. Looking at past instances where SUPN's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 227 cases where SUPN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SUPN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.992) is normal, around the industry mean (59.679). SUPN's P/E Ratio (1677.000) is considerably higher than the industry average of (89.540). SUPN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.913). Dividend Yield (0.000) settles around the average of (0.120) among similar stocks. P/S Ratio (3.065) is also within normal values, averaging (19.827).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

SUPN is expected to report earnings to fall 52.65% to 32 cents per share on February 25

Supernus Pharmaceuticals SUPN Stock Earnings Reports
Q4'24
Est.
$0.33
Q3'24
Beat
by $0.25
Q2'24
Beat
by $0.37
Q1'24
Missed
by $0.38
Q4'23
Missed
by $0.54
The last earnings report on November 04 showed earnings per share of 68 cents, beating the estimate of 43 cents. With 758.07K shares outstanding, the current market capitalization sits at 1.84B.
A.I. Advisor
published General Information

General Information

a developer for the treatment of central nervous system

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
9715 Key West Avenue
Phone
+1 301 838-2500
Employees
652
Web
https://www.supernus.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY611.491.79
+0.29%
SPDR® S&P 500® ETF Trust
AAPL244.47-0.13
-0.05%
Apple
GME26.97-0.03
-0.11%
GameStop Corp
BTC.X95539.550000-233.835940
-0.24%
Bitcoin cryptocurrency
TSLA354.11-1.73
-0.49%
Tesla

SUPN and Stocks

Correlation & Price change

A.I.dvisor tells us that SUPN and DVAX have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SUPN and DVAX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SUPN
1D Price
Change %
SUPN100%
+1.64%
DVAX - SUPN
33%
Poorly correlated
+0.86%
AMRX - SUPN
28%
Poorly correlated
+0.78%
AQST - SUPN
27%
Poorly correlated
-5.12%
AMPH - SUPN
26%
Poorly correlated
-0.87%
COLL - SUPN
26%
Poorly correlated
+0.17%
More